Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa, multicenter, randomized, double-blind, vehicle-controlled clinical trial to investigate topically applied DUR-928 in patients with plaque Psoriasis

Trial Profile

A Phase IIa, multicenter, randomized, double-blind, vehicle-controlled clinical trial to investigate topically applied DUR-928 in patients with plaque Psoriasis

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs DUR 928 (Primary)
  • Indications Plaque psoriasis
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 07 Jan 2019 According to a DURECT Corporation media release, dosing in this trial will begin in this quarter with top line data expected in the second half of 2019.
    • 07 Nov 2018 According to a DURECT Corporation media release, plan to initiate in the first quarter of 2019.
    • 12 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top